Onconetix, Inc.
ONCO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.00 | -0.00 | -1.53 |
| FCF Yield | -608.46% | -402.54% | -64.34% | -0.32% |
| EV / EBITDA | -0.18 | -0.24 | 0.91 | -185.25 |
| Quality | ||||
| ROIC | -286.99% | -45.02% | -60.22% | -236.24% |
| Gross Margin | 41.80% | -1,927.93% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.18 | 0.36 | 0.65 | 0.60 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 22.82% | -57.01% | -324.45% | -17.47% |
| Safety | ||||
| Net Debt / EBITDA | -0.15 | -0.15 | 1.92 | 0.57 |
| Interest Coverage | -40.13 | -53.65 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 22.93 | 3.26 | 0.00 | 0.00 |
| Cash Conversion Cycle | -911.23 | -583.26 | -81,049.03 | -43,486.88 |